BRMS1 inhibits expression of NF-κB subunit p65, uPA and OPN in ovarian cancer cells

Background: Breast cancer metastasis suppressor 1 (BRMS1) is a potent metastasis suppressor of various types of malignancies, including melanoma and ovarian cancer. Unfortunately, the clinical data regarding its role as a true metastatic suppressor and its efficacy as a prognostic marker and therapeutic target remain controversial. This study was designed to investigate the effect of BRMS1 on the invasion and metastasis of human ovarian cancer cells and its potential underlying mechanisms. Materials and Methods: BRMS1 small interfering RNAs (siRNAs) or control siRNAs were transfected into the OVCAR3 human ovarian cancer cell line. Invasion and migration activities were assessed using the Transwell invasion and migration assay. Protein levels of nuclear factor-κB (NF-κB) subunit p65, osteopontin (OPN) and urokinase- type plasminogen activator (uPA) were evaluated by Western blot, immunofluorescence and immunocytochemistry methods. Results: Successful knockdown of BRMS1 was verified by quantitative real-time RT-PCR and Western blot. The invasion and migration capacities of OVCAR3 cells were significantly enhanced in the BRMS1-silenced group, compared to controls (p < 0.05). Silencing of BRMS1 significantly induced the expression of NF-κB subunit, p65, uPA, and OPN proteins. Conclusions: BRMS1 inhibits expression of p65, uPA and OPN protein. In turn, this leads to inhibition of ovarian cancer cell invasion and metastasis. This study unveils a potential novel mechanism by which BRMS1 inhibits metastasis of ovarian cancer cells.

BRMS1; Ovarian cancer cells; Metastasis; uPA; OPN; NF-κB/p65.

[1] Miyazaki T., Kato H., Shitara Y., Yoshikawa M., Tajima K., Masuda N. et al.: “Mutation and expression of the metastasis suppressor gene KAI1 in esophageal squamous cell carcinoma”. Cancer, 2000, 89, 955.

[2] Hsu N.Y., Chen C.Y., Hsu C.P., Lin T.Y., Chou M.C., Chiou S.H. et al.: “Prognostic significance of expression of nm23-H1 and focal adhesion kinase in non-small cell lung cancer”. Oncol. Rep., 2007, 18, 81.

[3] Li H.Z., Wang Y., Gao Y., Shao J., Zhao X.L., Deng W.M. et al.: “Effects of raf kinase inhibitor protein expression on metastasis and progression of human epithelial ovarian cancer”. Mol. Cancer Res., 2008, 6, 917.

[4] Seraj M.J., Samant R.S., Verderame M.F., Welch D.R.: “Functional evidence for a novel human breast carcinoma metastasis suppressor, BRMS1, encoded at chromosome 11q13”. Cancer Res., 2000, 60, 2764.

[5] Yoshida B.A., Sokoloff M.M., Welch D.R., Rinker-Schaeffer C.W.: “Metastasissuppressor genes: a review and perspective on an emerging field”. J. Natl. Cancer Inst., 2000, 92, 1717.

[6] Shevde L.A., Welch D.R.: “Metastasis suppressor pathways-an evolving paradigm”. Cancer Lett., 2003, 198, 1.

[7] Berger J.C., Vander Griend D., Stadler W.M., Rinker-Schaeffer C.: “Metastasis suppressor genes: signal transduction, cross-talk and the potential for modulating the behavior of metastatic cells”. Anti-Cancer Drugs, 2004, 15, 559.

[8] Barnes P.J., Karin M.: “Nuclear factor- κB: a pivotal transcription factor in chronic inflammatory diseases”. N. Engl. J. Med., 1997, 336, 1066.

[9] Sliva D., Rizzo M.T., English D.: “Phosphatidylinositol 3-kinase and NF-κB regulate motility of invasive MDA-MB-231 human breast cancer cells by the secretion of urokinase-type plasminogen activator”. J. Biol. Chem., 2002, 277, 3150.

[10] Karashima T., Sweeney P., Kamat A., Huang S., Kim S.J., Bar-Eli M., et al.: “Nuclear factor-κB mediates angiogenesis and metastasis of human bladder cancer through the regulation of interleukin-8”. Clin. Cancer Res., 2003, 9, 2786.

[11] Cicek M., Fukuyama R., Welch D.R., Sizemore N., Casey G.: “Breast cancer metastasis suppressor 1 inhibits gene expression by targeting nuclear factor-kappaB activity”. Cancer Res., 2005, 65, 3586.

[12] Brooks S.A., Lomax-Browne H.J., Carter T.M., Kinch C.E., Hall D. M.: “Molecular interactions in cancer cell metastasis”. Acta Histochem., 2010, 112, 3.

[13] Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J.: “Cancer statistics”. 2009, CA Cancer J. Clin., 2009, 59, 225.

[14] Jiang J., Xia M., Feng J.B., Kong B.H.: “Inhibitory effect of breast cancer metastasis suppressor l gene on metastasis of human ovarian cancer cell in vitro and in vivo”. Zhong hua Fu Chan Ke Za Zhi, 2007, 42, 398.

[15] Metge B.J., Liu S., Riker A.I., Fodstad O., Samant R.S., Shevde L. A.: “Elevated osteopontin levels in metastatic melanoma correlate with epigenetic silencing of breast cancer metastasis suppressor 1”. Oncology, 2010, 78, 75.

[16] Seraj M.J., Harding M.A., Gildea J.J., Welch D.R.: “Theodorescu D. The relationship of BRMS1 and RhoGDI2 gene expression to metastatic potential in lineage related human bladder cancer cell lines”. Clin. Exp. Metastasis, 2000, 18, 519.

[17] Liotta L.A., Kohn E.C.: “The microenvironment of the tumorhost interface”. Nature, 2001, 411, 375.

[18] Schmalfeldt B., Prechtel D., Hatting K., Spathe K., Rutke S., Konik E., et al.: “Increased expression of matrix metalloproteinases (MMP-2), MMP-9 and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer”. Clin. Cancer Res., 2001, 7, 2396.

[19] Wang L., Madigan M.C., Chen H., Liu F., Patterson K.I., Beretov J., et al.: “Expression of urokinase plasminogen activator and its receptor in advanced epithelial ovarian cancer patients”. Gynecol. Oncol., 2009, 114, 265.

[20] Das R., Philip S., Mahabeleshwar G.H., Bulbule A., Kundu G.C.: “Osteopontin: it's role in regulation of cell motility and nuclear factor kappa B-mediated urokinase type plasminogen activator expression”. IUBMB Life, 2005, 57, 441.

[21] Cicek M., Fukuyama R., Cicek M.S., Sizemore S., Welch D.R., Sizemore N., et al.: “BRMS1 contributes to the negative regulation of uPA gene expression through recruitment of HDAC1 to the NF-kappaB binding site of the uPA promoter”. Clin. Exp. Metastasis, 2009, 26, 229.

[22] Ghosh S., May M.J., Kopp E.B.: “NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses”. Annu. Rev. Immunol., 1998, 16, 225.

[23] Pahl H.L.: “Activators and target genes of Rel/NF-kappaB tran-scription factors”. Oncogene, 1999, 18, 6853.

[24] Philip S., Bulbule A., Kundu G.C.: “Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-kappa B-mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells”. J. Biol. Chem., 2001, 276, 44926.

[25] Philip S., Kundu G.C.: “Osteopontin induces nuclear factor kappa B- mediated promatrix metalloproteinase-2 activation through I kappa B alpha /IKK signaling pathways and curcumin (diferu-lolylmethane) down-regulates these pathways”. J. Biol. Chem., 2003, 278, 14487.

[26] Dutta S., Wang F.Q., Fishman D.A.: “The dire need to develop a clinically validated screening method for the detection of early-stage ovarian cancer”. Biomark Med., 2010, 4, 437

[27] Huang S., Deguzman A., Bucana C.D., Fidler I.J.: “Nuclear factor-κB activity correlates with growth, angiogenesis and metastasis of human melanoma cells in nude mice”. Clin. Cancer Res., 2000, 6, 2573.

[28] Gapuzan M.E., Yufit P.V., Gilmore T.D.: “Immortalized embryonic mouse fibroblasts lacking the RelA subunit of transcription factor NF-κB have a malignantly transformed phenotype”. Oncogene, 2002, 21, 2484.

[29] Samant R.S., Clark D.W., Fillmore R.A., Cicek M., Metge B.J., Chandramouli K.H., et al.: “Breast cancer metastasis suppressor 1 (BRMS1) inhibits osteopontin transcription by abrogating NF-kappaB activation”. Mol. Cancer, 2007, 6, 6.

[30] Oates A.J., Barraclough R., Rudland P.S.: “The role of osteopontin in tumorigenesis and metastasis”. Invasion Metastasis, 1997, 17, 1.

[31] Weber G.F.: “The metastasis gene osteopontin: a candidate target for cancer therapy”. Biochim. Biophys. Acta, 2001, 1552, 61.

[32] Hedley B.D., Welch D.R., Allan A.L., Al-Katib W., Dales D.W., Postenka C.O., et al.: “Downregulation of osteopontin contributes to metastasis suppression by breast cancer metastasis suppressor 1”. Int. J. Cancer, 2008, 123, 526.